Compound News and Research

RSS

WuXi PharmaTech's Shanghai c-GMP manufacturing facility receives MPA compliance certificate

WuXi PharmaTech (WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it received the formal certificate of GMP compliance from the Medical Products Agency (MPA) of Sweden, acting on behalf of the European Medicines Agency (EMEA), for its c-GMP drug product manufacturing and analytical testing facilities located in Shanghai.

24 Feb 2010

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma.

23 Feb 2010

Tel Aviv University unveils new synthetic supplement to stall age-related memory loss

Those who live in industrialized countries have easy access to healthy food and nutritional supplements, but magnesium deficiencies are still common. That's a problem because new research from Tel Aviv University suggests that magnesium, a key nutrient for the functioning of memory, may be even more critical than previously thought for the neurons of children and healthy brain cells in adults.

23 Feb 2010

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidity, including the development of acute lung transplant rejection in 10% to 20% of infected patients.

22 Feb 2010

Researchers develop new tool to understand how cancer grows

Researchers have a new tool to understand how cancers grow -- and with it a new opportunity to identify novel cancer drugs. They've been able to break apart human prostate tissue, extract the stem cells in that tissue, and alter those cells genetically so that they spur cancer.

22 Feb 2010

Janssen-Cilag International's European MAA for ZEFTERA: CHMP adopts negative opinion

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on its Marketing Authorisation Application (MAA) for the antibiotic ZEFTERA(TM) (ceftobiprole medocaril), for the treatment of complicated skin and soft tissue infections.

19 Feb 2010

Kinesin protein motor shuttles cargo within cells and helps cells divide by rocking like a seesaw

Life's smallest motor, a protein that shuttles cargo within cells and helps cells divide, does so by rocking up and down like a seesaw, according to research conducted by scientists at the U.S. Department of Energy's Lawrence Berkeley National Laboratory and Brandeis University.

19 Feb 2010

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets.

19 Feb 2010

AGH neurosurgeons explore new therapeutic approach for brain tumor

Neurosurgeons at Allegheny General Hospital (AGH) are exploring use of a drug that illuminates brain tumor cells to determine if the experimental visualization technique will enhance their ability to surgically excise tumors and improve patient survival.

19 Feb 2010

Research shows natural compound in marine sponges reduces cancer cell motility

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham, formerly Burnham Institute for Medical Research) led by Kristiina Vuori, M.D., Ph.D., have discovered that the natural compound sceptrin, which is found in marine sponges, reduces cancer cell motility (movement) and has very low toxicity.

19 Feb 2010

Poor prescription practices among doctors may increase antibiotic resistance

A new paper in the February 17th edition of the journal Molecular Cell describes how exposure to low levels of antibiotics increases mutations in E. coli and Staphylococcus bacteria hundreds of times more than normal, making the creation of drug-resistant strains more likely.

19 Feb 2010

Ventas reports 7.8% increase in normalized FFO for year ended December 31, 2009

Ventas, Inc. said today that normalized Funds From Operations (“FFO”) for the year ended December 31, 2009 increased 7.8 percent to $409.0 million, from $379.5 million for the comparable 2008 period.

18 Feb 2010

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Incyte Corporation today reported fourth quarter and full year 2009 financial results, provided an update on key fourth quarter accomplishments and 2010 objectives, and announced its 2010 financial guidance.

18 Feb 2010

INC Research creates management program for strategic clinical delivery alliances with pharma and biotechnology customers

INC Research ®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, has created an Alliance Partnerships program dedicated to the creation and management of strategic clinical delivery alliances with pharmaceutical and biotechnology customers. Tim Dietlin has been appointed VP, Alliance Development to lead this effort on structuring alliance relationships based on joint strategic objectives rather than service level agreements.

18 Feb 2010

PK/PD data demonstrates clear relationship between TBR-652 plasma concentrations and antiviral activity

Pharmacokinetic/pharmacodynamic (PK/PD) data for TBR-652, which is being developed by Tobira Therapeutics for the treatment of HIV infection, show a strong relationship between drug exposure and viral suppression with this next-generation CCR5 receptor antagonist. These data were presented here today at the 17th Conference on Retroviruses and Opportunistic Infections (CROI).

18 Feb 2010

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Catalyst Pharmaceutical Partners, Inc. announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco.

18 Feb 2010

Aptuit develops proprietary production screen to understand API and drug formulations

Aptuit, Inc., today announced that it has developed a proprietary production screen to enable a better understanding of active pharmaceutical ingredients (API) and drug formulations earlier in the product lifecycle. The production screen applies advanced theoretical developments in solid-state chemistry to address challenges at the most critical interfaces in the drug development process.

18 Feb 2010

PositiveID acquires intellectual property rights and assets of Easy Check Medical Diagnostics

PositiveID Corporation announced today that it has acquired intellectual property rights and assets of Easy Check Medical Diagnostics, LLC, to expand its portfolio of non-invasive glucose-level testing products and diabetes management tools under development. Easy Check has two primary products under development: the Easy Check breath glucose detection system and the iGlucose™ wireless communication device.

17 Feb 2010

Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline

Tioga Pharmaceuticals, Inc. today announced the closing of an $18 million equity financing. Current investors Forward Ventures, New Leaf Venture Partners and BB Biotech Ventures were joined by new investor Genesys Capital Partners.

17 Feb 2010

Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes

Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.

17 Feb 2010

Compound News and Research

WuXi PharmaTech's Shanghai c-GMP manufacturing facility receives MPA compliance certificate

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

Tel Aviv University unveils new synthetic supplement to stall age-related memory loss

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Researchers develop new tool to understand how cancer grows

Janssen-Cilag International's European MAA for ZEFTERA: CHMP adopts negative opinion

Kinesin protein motor shuttles cargo within cells and helps cells divide by rocking like a seesaw

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

AGH neurosurgeons explore new therapeutic approach for brain tumor

Research shows natural compound in marine sponges reduces cancer cell motility

Poor prescription practices among doctors may increase antibiotic resistance

Ventas reports 7.8% increase in normalized FFO for year ended December 31, 2009

Incyte announces 2009 financial results and key fourth-quarter accomplishments

INC Research creates management program for strategic clinical delivery alliances with pharma and biotechnology customers

PK/PD data demonstrates clear relationship between TBR-652 plasma concentrations and antiviral activity

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Aptuit develops proprietary production screen to understand API and drug formulations

PositiveID acquires intellectual property rights and assets of Easy Check Medical Diagnostics

Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline

Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News